Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Cell signalling
Dedifferentiated liposarcoma
Genomic mutation
MDM2 amplification
Well-differentiated liposarcoma
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
01
2021
accepted:
16
04
2021
pubmed:
25
4
2021
medline:
10
6
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Well-differentiated liposarcoma (WDLPS) is the most frequent subtype of liposarcoma and may transform into dedifferentiated liposarcoma (DDLPS) which is a more aggressive subtype. Retroperitoneal lesions of WDLPS/DDLPS tend to recur repeatedly due to incomplete resections, and adjuvant chemotherapy and radiotherapy have little effect on patient survival. Consequently, identifying therapeutic targets and developing targeted drugs is critical for improving the outcome of WDLPS/DDLPS patients. In this review, we summarised the mutational landscape of WDLPS/DDLPS from recent studies focusing on potential oncogenic drivers and the development of molecular targeted drugs for DDLPS. Due to the limited number of studies on the molecular networks driving WDLPS to DDLPS development, we looked at other dedifferentiation-related tumours to identify potential parallel mechanisms that could be involved in the dedifferentiation process generating DDLPS.
Identifiants
pubmed: 33893924
doi: 10.1007/s11033-021-06362-5
pii: 10.1007/s11033-021-06362-5
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3637-3647Références
World Health Organization classification of soft tissue and bone tumours (2020) 5th ed, vol. 3. Lyon: IARC Press
Pedeutour F et al (1999) Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 24(1):30–41
pubmed: 9892106
Hoffman A et al (2011) New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat 14(1):52–66
pubmed: 21169051
Mandahl N et al (2017) Scattered genomic amplification in dedifferentiated liposarcoma. Mol Cytogenet 10:25
pubmed: 28652867
pmcid: 5483303
Mavrogenis AF, Papagelopoulos PJ (2013) Well-differentiated liposarcoma. Atlas Genet Cytogenet Oncol Haematol 8
Matthews A, Tang M, Cooper K (2010) Cytogenetic aberrations in soft tissue tumors harvested from fresh tissue submitted for surgical pathology: a single institutional experience. Int J Surg Pathol 18(4):260–267
pubmed: 19776087
Momand J et al (1998) The MDM2 gene amplification database. Nucleic Acids Res 26(15):3453–3459
pubmed: 9671804
pmcid: 147746
Kanoe H et al (1998) Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Anticancer Res 18(4A):2317–2321
pubmed: 9703873
Shimada S et al (2006) The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol 37(9):1123–1129
pubmed: 16938516
Aleixo PB et al (2009) Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 62(12):1127–1135
pubmed: 19946100
Evans HL (1979) Liposarcoma—study of 55 cases with a reassessment of its classification. Am J Surg Pathol 3(6):507–523
pubmed: 534388
Keung EZ et al (2014) Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg 218(2):206–217
pubmed: 24315890
Ghadimi MP et al (2011) Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol 18(13):3762–3770
pubmed: 21614627
Keung EZ et al (2018) The clinical behavior of well differentiated liposarcoma can be extremely variable: a retrospective cohort study at a major sarcoma center. J Surg Oncol 117(8):1799–1805
pubmed: 29723411
pmcid: 6904950
Lucas DR et al (1994) Well-differentiated liposarcoma. The Mayo clinic experience with 58 cases. Am J Clin Pathol 102(5):677–683
pubmed: 7942636
Lahat G et al (2008) Resectable well-differentiated versus dedifferentiated liposarcomas: two Different diseases possibly requiring Different treatment approaches. Ann Surg Oncol 15(6):1585–1593
pubmed: 18398663
Bill KL et al (2016) SAR405838: A Novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res 22(5):1150–1160
pubmed: 26475335
Ray-Coquard I et al (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13(11):1133–1140
pubmed: 23084521
Kurzrock R et al (2012) A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. J Clin Oncol 30(15).
de Jonge M et al (2017) A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer 76:144–151
pubmed: 28324749
Wagner AJ et al (2017) Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J Clin Oncol 35(12):1304–1311
pubmed: 28240971
pmcid: 5946729
Laroche-Clary A et al (2017) Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J Hematol Oncol 10(1):123
pubmed: 28629371
pmcid: 5477309
Serguienko A et al (2020) Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clin Sarcoma Res 10(1):4
pubmed: 32158531
pmcid: 7057454
Hirata M et al (2019) Integrated exome and RNA sequencing of dedifferentiated liposarcoma. Nat Commun 10(1):5683
pubmed: 31831742
pmcid: 6908635
Amin-Mansour A et al (2019) Genomic evolutionary patterns of leiomyosarcoma and liposarcoma. Clin Cancer Res 25(16):5135–5142
pubmed: 31164371
pmcid: 7341441
Beird HC et al (2018) Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud 4(2):a002386
pubmed: 29610390
pmcid: 5880260
Somaiah N et al (2018) Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891–19899
pubmed: 29731991
pmcid: 5929434
Asano N et al (2017) Frequent amplification of receptor tyrosine kinase genes in well-differentiated/dedifferentiated liposarcoma. Oncotarget 8(8):12941–12952
pubmed: 28099935
pmcid: 5355068
Mazzu YZ et al (2017) miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. Can Res 77(21):5728–5740
Creytens D et al (2015) Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis. Anticancer Res 35(4):1835–1842
pubmed: 25862836
Ugras S et al (2011) Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 71(17):5659–5669
pubmed: 21693658
pmcid: 3165140
Zhou Y et al (2014) Liposarcoma miRNA signatures identified from genome-wide miRNA expression profiling. Future Oncol 10(8):1373–1386
pubmed: 25052748
Lazar AJ et al (2017) Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950
pmcid: 5693358
Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10(6):1565–1569
pubmed: 2026149
pmcid: 452821
Jour G et al (2015) Prognostic relevance of Federation Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol 28(1):37–47
pubmed: 25059573
Ricciotti RW et al (2017) High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: a cytogenomic microarray analysis of 47 cases. Cancer Genet 218:69–80
pubmed: 29153098
Bill KLJ et al (2019) Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist 24(7):989–996
pubmed: 31019022
pmcid: 6656442
Kruiswijk F, Labuschagne CF, Vousden KH (2015) p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16(7):393–405
pubmed: 26122615
Momand J et al (1992) The Mdm2 oncogene product forms a complex with the P53 protein and inhibits P53-mediated transactivation. Cell 69(7):1237–1245
pubmed: 1535557
Haupt Y et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296–299
pubmed: 9153395
Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420(1):25–27
pubmed: 9450543
Vassilev LT et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844–848
pubmed: 14704432
Burgess A et al (2016) Clinical overview of MDM2/X-targeted therapies. Frontiers Oncol 6:7
Ding Q et al (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56(14):5979–5983
pubmed: 23808545
Laroche A et al (2017) MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas. Oncotarget 8(33):53968–53977
pubmed: 28903316
pmcid: 5589555
Roy S et al (2020) MDM2 antagonists induce a paradoxical activation of Erk1/2 through a P53-dependent mechanism in dedifferentiated liposarcomas: implications for combinatorial strategies. Cancers (Basel) 12(8):2253
Dadone-Montaudie B et al (2020) Novel therapeutic insights in dedifferentiated liposarcoma: a role for FGFR and MDM2 dual targeting. Cancers (Basel) 12(10):3058
Bauer TM et al (2018) A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36(15):11514–11514
Rasco DW et al (2019) A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. J Clin Oncol 37(15):3126–3126
Ozenne P et al (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127(10):2239–2247
pubmed: 20549699
Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1(14):1001–1008
pubmed: 14707283
pmcid: 14707283
Riscal R et al (2016) Chromatin-bound MDM2 regulates serine metabolism and redox homeostasis independently of p53. Mol Cell 62(6):890–902
pubmed: 27264869
Cisse MY et al (2020) Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Translation Med 12(547):2163
Binh MB et al (2005) MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29(10):1340–1347
pubmed: 16160477
Matsushime H et al (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71(2):323–334
pubmed: 1423597
Lee SE et al (2014) High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histol Histopathol 29(1):127–138
pubmed: 23852861
Lee S et al (2014) CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen. PLoS ONE 9(8):e99452
pubmed: 25121597
pmcid: 4133208
Saada-Bouzid E et al (2015) Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol 28(11):1404–1414
pubmed: 26336885
Zhang YX et al (2014) Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther 13(9):2184–2193
pubmed: 25028469
Dickson MA et al (2013) Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31(16):2024–2028
pubmed: 23569312
pmcid: 3661937
Kamb A et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264(5157):436–440
pubmed: 8153634
Li J, Poi MJ, Tsai MD (2011) Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry 50(25):5566–5582
pubmed: 21619050
pmcid: 3127263
Kato J et al (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7(3):331–342
pubmed: 8449399
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366(6456):704–707
pubmed: 8259215
Italiano A et al (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15(18):5696–5703
pubmed: 19737942
Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404
Gao JJ et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1
pubmed: 4160307
pmcid: 4160307
Thanos D, Maniatis T (1992) The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71(5):777–789
pubmed: 1330326
Xi Y et al (2016) HMGA2 promotes adipogenesis by activating C/EBPbeta-mediated expression of PPARgamma. Biochem Biophys Res Commun 472(4):617–623
pubmed: 26966068
Gattas GJF et al (1999) HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosom Cancer 25(4):316–322
pubmed: 10398424
Nishino J et al (2008) Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 135(2):227–239
pubmed: 18957199
pmcid: 2582221
Narita M et al (2006) A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126(3):503–514
pubmed: 16901784
Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7(12):899–910
pubmed: 18004397
Pentimalli F et al (2003) Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Can Res 63(21):7423–7427
Jankowski SA et al (1994) SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins. Oncogene 9(4):1205–1211
pubmed: 8134123
Yanez-Mo M et al (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19(9):434–446
pubmed: 19709882
Hemler ME (2014) Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 14(1):49–60
pubmed: 24505619
Denis CJ et al (2013) Carboxypeptidase M in apoptosis, adipogenesis and cancer. Clin Chim Acta 415:306–316
pubmed: 23178445
Kanojia D et al (2015) Genomic landscape of liposarcoma. Oncotarget 6(40):42429–42444
pubmed: 26643872
pmcid: 4767443
Park JH, Roeder RG (2006) GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol Cell Biol 26(11):4006–4016
pubmed: 16705155
pmcid: 1489109
Barretina J et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42(8):715–721
pubmed: 20601955
pmcid: 2911503
Kouhara H et al (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89(5):693–702
pubmed: 9182757
pmcid: 9182757
Wang X et al (2011) High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer 50(11):849–858
pubmed: 21793095
Zhang K et al (2013) Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res 73(4):1298–1307
pubmed: 23393200
Hanes R et al (2016) Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. Oncotarget 7(34):54583–54595
pubmed: 27409346
pmcid: 5342366
Hanes R et al (2019) Preclinical evaluation of the Pan-FGFR inhibitor LY2874455 in FRS2-amplified liposarcoma. Cells 8(2):189
pmcid: 6406403
Snyder EL et al (2009) c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 218(3):292–300
pubmed: 19449367
Sioletic S et al (2014) c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol 234(2):190–202
pubmed: 24852265
pmcid: 4472460
Toulmonde M et al (2015) Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. Ann Oncol 26(7):1465–1470
pubmed: 26041763
pmcid: 4478976
Zhang P et al (2012) MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res 72(7):1751–1762
pubmed: 22350414
pmcid: 3319789
Vincenzi B et al (2015) Deregulation of dicer and mir-155 expression in liposarcoma. Oncotarget 6(12):10586–10591
pubmed: 25888631
pmcid: 4496377
Yu PY et al (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
pubmed: 29983640
pmcid: 6019219
Cao Y, Zheng J, Lv C (2019) miR-199a-3p knockdown inhibits dedifferentiated liposarcoma (DDLPS) cell viability and enhances apoptosis through targeting casein kinase-1 alpha (CK1α). RSC Adv 9(39):22755–22763
Takada I, Kouzmenko AP, Kato S (2009) Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5(8):442–447
pubmed: 19581903
Chen Q et al (2016) Fate decision of mesenchymal stem cells: adipocytes or osteoblasts. Cell Death Differ 23(7):1128–1139
pubmed: 26868907
pmcid: 4946886
Tammela T et al (2017) A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature 545(7654):355–359
pubmed: 28489818
pmcid: 5903678
Nabhan AN et al (2018) Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359(6380):1118–1123
pubmed: 29420258
pmcid: 5997265
Caplan AI (1991) Mesenchymal stem cells. J Orthop Res 9(5):641–650
pubmed: 1870029
pmcid: 1870029
Ross SE et al (2000) Inhibition of adipogenesis by Wnt signaling. Science 289(5481):950–953
pubmed: 10937998
Hanna A, Shevde LA (2016) Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer 15:24
pubmed: 26988232
pmcid: 4797362
Rusiecki D et al (2017) Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. Hum Pathol 59:125–130
pubmed: 27597523
Suh JM et al (2006) Hedgehog signaling plays a conserved role in inhibiting fat formation. Cell Metab 3(1):25–34
pubmed: 16399502
Drummond CJ et al (2018) Hedgehog pathway drives fusion-negative rhabdomyosarcoma initiated from non-myogenic endothelial progenitors. Cancer Cell 33(1):108–124
pubmed: 29316425
pmcid: 5790179
Siebel C, Lendahl U (2017) Notch signaling in development, tissue homeostasis, and disease. Physiol Rev 97(4):1235–1294
pubmed: 28794168
Sandel DA et al (2018) Notch3 is involved in adipogenesis of human adipose-derived stromal/stem cells. Biochimie 150:31–36
pubmed: 29709509
Nueda ML et al (2018) DLK proteins modulate NOTCH signaling to influence a brown or white 3T3-L1 adipocyte fate. Sci Reports 8:16923
Bi P et al (2016) Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice. J Exp Med 213(10):2019–2037
pubmed: 27573812
pmcid: 5030803
Chaux A et al (2012) Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas. Urology 80(3):736
pubmed: 22698476